Stocks · News reference

TG Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Aug 3, 2026, 2:12 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 21, 2026, 6:02 PM
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
TG Therapeutics announced updated clinical data for its multiple sclerosis portfolio, including long-term follow-up and new trial results, at the 10th Joint ACTRIMS-ECTRIMS Meeting.
TGTX
BenzingaOct 12, 2026, 11:31 AMBenzinga Newsdesk
TG Therapeutics Says BRIUMVI Showed 44% Lower Risk Of MS Disability Progression vs. Ocrelizumab, 49% vs. Ofatumumab In Indirect Comparison
TGTX
BenzingaSep 25, 2026, 8:19 PMChandrima Sanyal
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
AXSM CYTK ETON HROW TGTX
BenzingaSep 1, 2026, 5:10 PMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $78 Price Target
TGTX